Sai Life Sciences IPO Date, Price, GMP, Review, Details, Issue Date, Lot Size, Allotment, Subscription Status
The Sai Life Sciences IPO will open on December 11, 2024, and close on December 13, 2024. This is a Book Built Issue, through which the company aims to raise approximately ₹3,042.62 crores. The offering includes a fresh issue of ₹3,042.62 crores and an offer for sale of up to 38,116,934 equity shares, each with a face value of ₹1.
The price band for the Sai Life Sciences IPO is set between ₹522 and ₹549 per share. The allocation is divided as follows: 35% for retail investors, 50% for Qualified Institutional Buyers (QIBs), and 15% for High Net-Worth Individuals (HNIs). The IPO is scheduled to list on both the BSE and NSE on December 18, 2024, with the allotment date set for December 16, 2024.
For the fiscal year 2024, Sai Life Sciences reported a revenue of ₹1,494.27 crores, compared to ₹1,245.11 crores in 2023. The company also saw a significant increase in profit, reporting ₹82.81 crores in 2024, up from ₹9.99 crores in 2023. Based on these financials, long-term investors are encouraged to consider applying for the IPO.
Sai Life Sciences IPO Details
- IPO Opening Date: December 11, 2024
- IPO Closing Date: December 13, 2024
- Face Value: ₹1 per Equity Share
- Price Band: ₹522 to ₹549 per Share
- Total Issue Size: Approximately ₹3,042.62 Crores
- Fresh Issue Size: Approximately ₹950.00 Crores
- Offer for Sale: Approximately 38,116,934 Equity Shares
- Issue Type: Book Built Issue
- Listing on: BSE & NSE
- Retail Quota: Up to 35%
- QIB Quota: Up to 50%
- NII Quota: Up to 15%
- Draft Red Herring Prospectus (DRHP): Click Here
- Red Herring Prospectus (RHP): Click Here
Sai Life Sciences IPO Market Lot Details
The minimum market lot for the Sai Life Sciences IPO is 27 shares, requiring an application amount of ₹14,823. Retail investors have the option to apply for up to 13 lots, which equals 351 shares, at a total cost of ₹192,699.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 27 | ₹14,823 |
| Retail Maximum | 13 | 351 | ₹192,699 |
| S-HNI Minimum | 14 | 378 | ₹207,522 |
| B-HNI Minimum | 68 | 1,836 | ₹1,007,964 |
Sai Life Sciences IPO Key Dates
The Sai Life Sciences IPO will open for subscription on December 11, 2024, and close on December 13, 2024. The allotment will be finalized on December 16, 2024, with refunds and credit to Demat accounts processed by December 17, 2024. The IPO is set to be listed on December 18, 2024.
| Event | Date |
|---|---|
| IPO Open Date | December 11, 2024 |
| IPO Close Date | December 13, 2024 |
| Basis of Allotment | December 16, 2024 |
| Refunds | December 17, 2024 |
| Credit to Demat Account | December 17, 2024 |
| IPO Listing Date | December 18, 2024 |
Promoters of Sai Life Sciences IPO
The promoters of Sai Life Sciences are:
- Kanumuri Ranga Raju
- Krishnam Raju Kanumuri
- Kanumuri Mytrey
- Sai Quest Syn Private Limited
- Sunflower Partners
- Lily Partners
- Marigold Partners
- Tulip Partners
About Sai Life Sciences IPO
Founded in January 1999, Sai Life Sciences Limited collaborates with innovative pharmaceutical and biotech companies, offering services in drug discovery, development, and manufacturing of small-molecule new chemical entities (NCE). As a Contract Research, Development, and Manufacturing Organization (CRDMO), Sai Life Sciences leverages its scientific expertise to address critical healthcare challenges. The company aims to develop medicines for currently incurable conditions, making a significant impact on the future of healthcare. Its adaptable services cater to both small clients and global pharmaceutical companies, contributing to impressive growth in CRDMO, outperforming competitors. The company has maintained consistent revenue and EBITDA growth from FY2022 to FY2024. Over its 24-year history, Sai Life Sciences has delivered a diverse range of NCE development programs, excelling in quality, price, and responsiveness.
Sai Life Sciences IPO Financial Overview
Sai Life Sciences reported the following financial figures:
- Revenue: ₹1,494.27 crores in FY2024, up from ₹1,245.11 crores in FY2023.
- Profit: ₹82.81 crores in FY2024, compared to ₹9.99 crores in FY2023.
| Period Ended | Revenue (₹ Cr.) | Expense (₹ Cr.) | Profit After Tax (₹ Cr.) | Assets (₹ Cr.) |
|---|---|---|---|---|
| 2022 | ₹897.74 | ₹888.05 | ₹6.23 | ₹2,164.23 |
| 2023 | ₹1,245.11 | ₹1,228.70 | ₹9.99 | ₹2,186.65 |
| 2024 | ₹1,494.27 | ₹1,385.04 | ₹82.81 | ₹2,275.14 |
| September 2024 | ₹693.35 | ₹656.09 | ₹28.01 | ₹2,476.78 |
Sai Life Sciences IPO Valuation – FY2024
Key performance indicators for Sai Life Sciences:
| KPI | Values |
|---|---|
| Return on Equity (ROE) | 8.49% |
| Return on Capital Employed (ROCE) | 10.26% |
| EBITDA Margin | 20.48% |
| PAT Margin | 5.65% |
| Debt-to-Equity Ratio | 0.75 |
| Earnings Per Share (EPS) | ₹4.57 (Basic) |
| Price/Earnings (P/E) Ratio | N/A |
| Return on Net Worth (RoNW) | 8.50% |
| Net Asset Value (NAV) | ₹53.83 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Divi’s Laboratories | ₹60.27 | 103.04 | 11.79% | ₹511.21 | ₹7,845.00 Cr. |
| Suven Pharmaceuticals | ₹11.80 | 109.37 | 14.64% | ₹94.04 | ₹1,051.35 Cr. |
| Syngene International | ₹12.71 | 73.59 | 11.98% | ₹105.91 | ₹3,488.60 Cr. |
Objects of the Issue
The funds raised through the IPO will be used for:
- Repayment or prepayment of outstanding borrowings, in whole or in part.
- General corporate purposes.
Sai Life Sciences IPO Review by Leading Firms
The IPO has been reviewed by the following firms:
- Canara Bank
- DRChoksey FinServ
- Emkay Global
- Hem Securities
- IDBI Capital
- Marwadi Shares
- Nirmal Bang
- SBICAP Securities
- Sharekhan
- SMC Global
- Sushil Finance
- Swastika Investmart
- Ventura Securities
- Geojit
- Reliance Securities
- Capital Market
- BP Wealth
- ICICIdirect
- Choice Broking
Sai Life Sciences IPO Registrar
Registrar: KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: sailifesciences.ipo@kfintech.com
Website: KFin Technologies IPO Status
IPO Lead Managers (Merchant Bankers)
- Kotak Mahindra Capital Company Limited
- Jefferies India Private Limited
- Morgan Stanley India Company Pvt Ltd
- IIFL Securities Ltd
Company Address
Sai Life Sciences Limited
Plot No. DS-7, IKP Knowledge Park
Turkapally Village, Shameerpet Mandal
Malkajgiri District, Hyderabad-500078
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: Sai Life Sciences
How to apply for the Sai Life Sciences IPO?
Investors can apply via ASBA online through their bank account or via UPI through stock brokers. Offline applications can also be made by filling out the form through stock brokers.
What is the Sai Life Sciences IPO issue size?
The issue size is ₹3,042.62 crores.
What is the Sai Life Sciences IPO price band?
The price band is ₹522 to ₹549 per share.
What is the Sai Life Sciences IPO lot size?
The minimum bid size is 27 shares for ₹14,823.
What is the Sai Life Sciences IPO allotment date?
The allotment date is December 16, 2024.
When will the Sai Life Sciences IPO be listed?
The listing date is December 18, 2024, on BSE & NSE.
Sai Life Sciences IPO FAQs
What is Sai Life Sciences IPO?
The Sai Life Sciences IPO is a mainboard IPO, raising ₹3,042.62 Crores. The price band is ₹522 to ₹549 per equity share. The IPO will be listed on BSE and NSE.
When will the Sai Life Sciences IPO open for subscription?
The IPO opens on December 11, 2024, and closes on December 13, 2024.
What is the allocation for investors in Sai Life Sciences IPO?
The allocation for investors is as follows:
- QIB: 50%
- NII: 15%
- Retail: 35%
